Danaher (NYSE:DHR) PT Raised to $271.00 at Robert W. Baird

Danaher (NYSE:DHR) had its price target boosted by equities research analysts at Robert W. Baird from $259.00 to $271.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the conglomerate’s stock. Robert W. Baird’s price objective indicates a potential upside of 10.24% from the stock’s current price.

Several other equities analysts have also recently commented on the company. KeyCorp boosted their target price on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Raymond James upped their price objective on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Citigroup upped their price objective on Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Royal Bank of Canada upped their price objective on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Finally, StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $270.00.

Danaher Price Performance

Danaher stock opened at $245.82 on Wednesday. Danaher has a 52 week low of $182.09 and a 52 week high of $259.00. The business has a 50-day simple moving average of $248.94 and a 200 day simple moving average of $230.88. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The stock has a market cap of $182.04 billion, a price-to-earnings ratio of 41.66, a PEG ratio of 4.24 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.48% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same period in the previous year, the business earned $2.36 earnings per share. The firm’s revenue was down 2.6% on a year-over-year basis. On average, research analysts forecast that Danaher will post 7.62 earnings per share for the current fiscal year.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the completion of the transaction, the senior vice president now owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Brian W. Ellis sold 4,000 shares of the stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the transaction, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The disclosure for this sale can be found here. Insiders sold 84,132 shares of company stock valued at $21,022,795 in the last 90 days. Insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DHR. Cape Investment Advisory Inc. bought a new position in Danaher during the 4th quarter valued at approximately $25,000. Tsfg LLC boosted its stake in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the last quarter. BKM Wealth Management LLC purchased a new stake in Danaher during the 4th quarter valued at $27,000. Wetzel Investment Advisors Inc. purchased a new stake in Danaher during the 4th quarter valued at $29,000. Finally, OFI Invest Asset Management purchased a new stake in Danaher during the 3rd quarter valued at $30,000. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.